A year in review (2022): Modulators and COVID19, the story goes on….
作者信息
Dillenhoefer Stefanie, Grogono Dorothy, Morales-Tirado Ana
机构信息
Department of Pediatric Pulmonology, Cystic Fibrosis Center, University Children's Hospital of Ruhr University Bochum at St. Josef-Hospital, 44791 Bochum, Germany.
Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge, CB2 0AY, UK.
出版信息
J Cyst Fibros. 2023 Mar;22(2):188-192. doi: 10.1016/j.jcf.2023.03.001. Epub 2023 Mar 6.
Abstract
摘要
相似文献
1
A year in review (2022): Modulators and COVID19, the story goes on….年度回顾（2022）：调节剂与新冠病毒，故事仍在继续……
J Cyst Fibros. 2023 Mar;22(2):188-192. doi: 10.1016/j.jcf.2023.03.001. Epub 2023 Mar 6.
2
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.西班牙囊性纤维化患者中 SARS-CoV-2 感染的影响：全国 CF-COVID19-西班牙调查的发病率和结果。
Respir Med. 2020 Aug-Sep;170:106062. doi: 10.1016/j.rmed.2020.106062. Epub 2020 Jun 8.
3
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.囊性纤维化跨膜电导调节因子调节剂可减弱健康供体和 COVID-19 患者血液中的血小板活化和聚集。
Eur Respir J. 2023 Mar 23;61(3). doi: 10.1183/13993003.02009-2022. Print 2023 Mar.
4
Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine.新冠疫情封锁期间，一名患有囊性纤维化的糖尿病前期患者使用甘精胰岛素长期治疗后出现糖尿病发作。
Ital J Pediatr. 2021 Jun 2;47(1):121. doi: 10.1186/s13052-021-01076-7.
5
Telehealth and CFTR modulators: Accelerating innovative models of cystic fibrosis care.远程医疗与囊性纤维化跨膜传导调节因子调节剂：加速囊性纤维化护理的创新模式
J Cyst Fibros. 2023 Jan;22(1):9-16. doi: 10.1016/j.jcf.2022.07.002. Epub 2022 Jul 22.
6
Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.囊性纤维化跨膜电导调节因子调节剂时代的晚期囊性纤维化肺病和肺移植
Semin Respir Crit Care Med. 2023 Apr;44(2):260-268. doi: 10.1055/s-0042-1758731. Epub 2023 Mar 9.
7
COVID-19 vaccine prioritisation for people with cystic fibrosis.针对囊性纤维化患者的新冠疫苗接种优先排序
J Cyst Fibros. 2021 Jul;20(4):715-716. doi: 10.1016/j.jcf.2021.03.028. Epub 2021 Apr 15.
8
Cystic fibrosis year in review 2019: Section 1 CFTR modulators.囊性纤维化年度回顾 2019：第 1 部分 CFTR 调节剂。
Pediatr Pulmonol. 2020 Dec;55(12):3236-3242. doi: 10.1002/ppul.25039. Epub 2020 Sep 1.
9
Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.囊性纤维化跨膜传导调节因子调节剂：囊性纤维化治疗的现状与未来。综述
Arch Argent Pediatr. 2019 Apr 1;117(2):e131-e136. doi: 10.5546/aap.2019.eng.e131.
10
Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVID-19?囊性纤维化基因突变携带者是 COVID-19 的潜在高脆弱人群吗？
J Cell Mol Med. 2020 Nov;24(22):13542-13545. doi: 10.1111/jcmm.15941. Epub 2020 Oct 3.
本文引用的文献
1
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.囊性纤维化 CFTR 变异体特异性治疗（包括调节剂）的护理标准。
J Cyst Fibros. 2023 Jan;22(1):17-30. doi: 10.1016/j.jcf.2022.10.002. Epub 2022 Oct 28.
2
Impact of COVID-19 on Lung Disease in People with Cystic Fibrosis: A 6-Month Follow-Up Study on Respiratory Outcomes.2019冠状病毒病对囊性纤维化患者肺部疾病的影响：一项关于呼吸结局的6个月随访研究
Biomedicines. 2022 Nov 1;10(11):2771. doi: 10.3390/biomedicines10112771.
3
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.调制治疗的囊性纤维化患者中停用或继续使用高渗盐水或脱氧核糖核酸酶 α（SIMPLIFY）：两项平行、多中心、开放标签、随机、对照、非劣效性试验的结果。
Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4.
4
Development of novel therapeutics for all individuals with CF (the future goes on).为所有 CF 患者开发新的治疗方法（未来可期）。
J Cyst Fibros. 2023 Mar;22 Suppl 1:S45-S49. doi: 10.1016/j.jcf.2022.10.007. Epub 2022 Oct 30.
5
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.依利卓卡非特/替扎卡非特/伊伐卡非特联合治疗囊性纤维化的胃肠道结局：报告的前景-GI。
J Cyst Fibros. 2023 Mar;22(2):282-289. doi: 10.1016/j.jcf.2022.10.003. Epub 2022 Oct 21.
6
Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding.先天性双侧白内障在子宫内和母乳喂养期间暴露于依利卓卡非他/特立氟胺/依伐卡托的新生儿中。
J Cyst Fibros. 2022 Nov;21(6):1074-1076. doi: 10.1016/j.jcf.2022.10.004. Epub 2022 Oct 18.
7
Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic.COVID-19 大流行期间囊性纤维化成人和儿童的临床结局。
J Cyst Fibros. 2023 May;22(3):581-586. doi: 10.1016/j.jcf.2022.09.006. Epub 2022 Sep 16.
8
Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review.囊性纤维化患者发生重症 COVID-19 的危险因素：一项系统综述。
Front Pediatr. 2022 Aug 8;10:958658. doi: 10.3389/fped.2022.958658. eCollection 2022.
9
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.依伐卡托钠/泰比卡托钠/埃他卡托钠在 和最小功能突变杂合子且年龄在 6 至 11 岁的囊性纤维化儿童中的疗效和安全性：一项 3b 期、随机、安慰剂对照研究。
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1361-1369. doi: 10.1164/rccm.202202-0392OC.
10
A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for .一项评估 Lumacaftor/Ivacaftor 在 1 岁以下囊性纤维化纯合子患儿中的疗效和安全性的 3 期、开放标签研究。
Am J Respir Crit Care Med. 2022 Nov 15;206(10):1239-1247. doi: 10.1164/rccm.202204-0734OC.
Zotero 插件